# SFX-01 After Subarachnoid Haemorrhage

> **NCT02614742** · PHASE2 · COMPLETED · sponsor: **Evgen Pharma** · enrollment: 90 (actual)

## Conditions studied

- Subarachnoid Hemorrhage, Spontaneous

## Interventions

- **DRUG:** SFX-01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02614742
- **Lead sponsor:** Evgen Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2019-09
- **Final completion:** 2019-11
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2020-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02614742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02614742, "SFX-01 After Subarachnoid Haemorrhage". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02614742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*